Canada - English - Health Canada

north american sun & medical - octinoxate; oxybenzone; octocrylene - cream - 7.5%; 6.0%; 10.0% - octinoxate 7.5%; oxybenzone 6.0%; octocrylene 10.0% - sunscreen agents

Canada - English - Health Canada

edgewell personal care canada, ulc - octocrylene; oxybenzone; avobenzone - lotion - 5%; 3%; 2% - octocrylene 5%; oxybenzone 3%; avobenzone 2% - sunscreen agents

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

brandt international llc - sulphonated aromatic acid dye - liquid - sulphonated aromatic acid dye dye active 93.0 g/l - marker

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

brandt international llc - nonoxinol 9; phosphoric acid derivatives - liquid - nonoxinol 9 emulsifiers & surfactants active 266.2 g/l; phosphoric acid derivatives mineral-phophorus-acid active 375.1 g/l - adjuvant

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

brandt international llc - di-1-p-menthene - emulsifiable concentrate - di-1-p-menthene ungrouped active 905.0 g/l - wetting agent

United States - English - NLM (National Library of Medicine)

meditrend, inc. dba progena professional formulations - echinacea, unspecified (unii: 4n9p6cc1dx) (echinacea, unspecified - unii:4n9p6cc1dx), baptisia tinctoria root (unii: 5ef0hwi5wu) (baptisia tinctoria root - unii:5ef0hwi5wu), goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), myrrh (unii: jc71gj1f3l) (myrrh - unii:jc71gj1f3l), nasturtium officinale (unii: yh89gmv676) (nasturtium officinale - unii:yh89gmv676), phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), fenugreek leaf (unii: 487ri96k8z) (fenugr - echinacea, unspecified 3 [hp_x] in 1 ml - purpose: relief from sneezing, runny nose, itchy eyes and sinus congestion. use: this product is a homeopathic dilution formulated to support the body's immunity for the temporary relief of allergies.

United States - English - NLM (National Library of Medicine)

quallent pharmaceuticals health llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole oral tablets are indicated for the treatment of: - schizophrenia - irritability associated with autistic disorder - treatment of tourette’s disorder aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see clinical considerations) . overall av

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - sodium fluoroacetate(0.18g/kg)+permethrin(10g/l) - vermin destroyer

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts o

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.